Filgotinib placebo

DRUG4 trials

Sponsors

Gilead Sciences

Conditions

Cutaneous Lupus ErythematosusLupus Membranous NephropathyRheumatoid ArthritisSjogren's Syndrome

Phase 2

Safety, Tolerability, and Efficacy of GS-9876 in Participants With Active Rheumatoid Arthritis on Background Therapy With Methotrexate

CompletedNCT02885181

Gilead SciencesRheumatoid Arthritis

Start: 2016-09-21End: 2017-09-20Updated: 2018-09-19

Study to Assess Safety and Efficacy of Filgotinib, Lanraplenib and Tirabrutinib in Adults With Active Sjogren's Syndrome

CompletedNCT03100942

Gilead SciencesSjogren's Syndrome

Start: 2017-05-01End: 2019-10-02Updated: 2020-10-23

Study to Evaluate Safety and Efficacy of Filgotinib and Lanraplenib in Females With Moderately-to-Severely Active Cutaneous Lupus Erythematosus (CLE)

CompletedNCT03134222

Gilead SciencesCutaneous Lupus Erythematosus

Start: 2017-05-24End: 2019-12-18Updated: 2020-06-09

Study to Evaluate the Safety and Efficacy of Filgotinib and Lanraplenib in Adults With Lupus Membranous Nephropathy (LMN)

CompletedNCT03285711

Gilead SciencesLupus Membranous Nephropathy

Start: 2017-10-06End: 2020-02-03Updated: 2020-05-18

Related Papers

Monitoramento do Horizonte Tecnológico (MHT) de Inibidores de Janus Quinase (JAKi) para o Tratamento de Lúpus Eritematoso Sistêmico (LES)

Epidemiologia e Serviços de Saúde2025-01-01

A multi-center, open-label, randomized study to explore efficacy and safety of baricitinib in active primary Sjogren’s syndrome patients

Trials2023-02-159 citations

Safety and efficacy of filgotinib, lanraplenib and tirabrutinib in Sjögren’s syndrome: a randomized, phase 2, double-blind, placebo-controlled study

Lara D. Veeken2022-04-0465 citations

Filgotinib or lanraplenib in moderate to severe cutaneous lupus erythematosus: a phase 2, randomized, double-blind, placebo-controlled study

Lara D. Veeken2021-09-0862 citations

Phase II, randomised, double-blind, multicentre study evaluating the safety and efficacy of filgotinib and lanraplenib in patients with lupus membranous nephropathy

RMD Open2020-12-0141 citations